Print  |  Close

Winship Cancer Institute of Emory University

Winship Cancer Institute NCI Designated Comprehensive Cancer Center
Winship Cancer Institute of Emory University
Atlanta, Georgia

Winship Cancer Institute of Emory University is Georgia's first and only comprehensive cancer center designated by the National Cancer Institute (NCI). Designation requires meeting rigorous criteria for the depth and breadth of basic science and clinical research, in addition to cancer prevention, control, and population/behavioral sciences. It requires effective collaboration among various disciplines and with community partners in private practice and in academic centers throughout Georgia and across the nation. With this recognition comes the responsibility to provide public information, education and outreach to other health care professionals and the community. NCI designation for Winship gives Georgians improved access to clinical trials and resources that may not be available elsewhere.

The Winship Cancer Institute (Winship) at Emory University is a multidisciplinary matrix center that supports, facilitates, coordinates, and centralizes cancer research, quality oncology care, education, and dissemination at Emory University and its affiliate institutions in order to reduce the burden of cancer, associated morbidity, and mortality in the state of Georgia, the Southeastern region, and the U.S. Winship is dedicated to the integration of innovative clinical and basic science research with outstanding patient care for the prevention, treatment and control of cancer.

1-888-946-7447
winshipcancer.emory.edu

Treatment Sites in Georgia

Primary Location

1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-1900 (p)
winshipcancer.emory.edu

driving directions

Doctors:

Nazmi Volkan Adsay MD
Michael R. Aho MD
Mehmet Akce MD
Mehrdad Alemozaffar MD
Olatunji B. Alese MD
Olatunji B. Alese MD
Pamela Blair Allen MD, MSc
Ana Antun MD
Jack Arbiser MD, PhD
Cletus A. Arciero MD
Martha L. Arellano MD
Bruce J. Barron MD
Deborah A. Baumgarten MD, MPH
Jonathan J. Beitler MD, MBA, FACR
Leon Bernal MD
George G. A. Birdsong MD
William G. Blum
Daniel J. Brat MD, PhD
Otis W. Brawley MD
Joan Cain MD, MSc
Grant W. Carlson MD
Bradley C. Carthon, MD, PhD
Amy Y. Chen MD
Cynthia Cohen MD
Jonathon B Cohen MD, MS
Michael A. Cohen MD, FACR
Laronna S Colbert MD
Ian R. Crocker MD, FACR
Walter J Curran, Jr. MD, FACR
Keith A. Delman MD, FACS
Maria Diab MD
Roberto R. Diaz MD
Scott H. Edelman MD
John William Eley MD, MPH
Bassel F El-Rayes MD
Tony Y Eng MD
Christopher R. Flowers MD
Sarah Friend MD
Sheryl A. Gabram-Mendola MD, MBA, FACS
Manila Gaddh , MD
Anthony Andrew Gal MD
Jacques Galipeau MD
Karen D. Godette MD
Keerthi Gogineni MD
Bruce D Goldsweig MD
Cathy L Graham MD, FACS
William J. Grist MD
Kathleen Gundry MD
Vikas A Gupta MD
Raghuveer K. Halkar MD
Chunhai Hao MD, PhD
Wayne B. Harris MD
R. Donald Harvey , PharmD
Natalyn N. Hawk MD
Leonard T. Heffner Jr., MD
Bruce W. Hershatter MD
Kristin Higgins MD
Charles E. Hill MD
Craig C Hofmeister MD, MPH
Chad A. Holder MD
Stephen B. Hunter MD
Sol Jacobs MD
Ashesh B. Jani MD
David L. Jaye MD
Jade Jones MD
Jonathan L. Kaufman MD
H. Jean Khoury MD, FACP
Kevin Kim MD
Adam M. Klein MD
Rebecca Bruner Klisovic MD
Jean L Koff MD
David A. Kooby MD
Vamsi K. Kota MD
Joan Kramer
Omer Kucuk MD
Ragini R Kudchadkar MD
J. David Lambeth MD, PhD
Jerome C. Landry MD
Amelia A. Langston MD
Stephen K. Lau MD
David H. Lawson MD
Mary Jo Lechowicz MD
Daniel J. Lee MD
Melinda Moore Lewis MD
Shiyong Li MD, PhD
Jolinta Y Lin MD
James V. Little MD
Sagar Lonial MD
Shishir K. Maithel MD
Anant Mandawat MD
Karen P. Mann MD, PhD
Viraj Master MD, PhD
Mark William McDonald MD
Morgan L. McLemore MD
Jane L Meisel MD
Daniel L. Miller MD
Leon Bernal- Mizrachi MD
David K Monson MD
Melvin Moore MD
Mario Mosunjac MD
Susan C. Muller DMD, MS
Padma C. Nadella MD
Mary S. Newell MD
Peter T. Nieh MD
Ajay K. Nooka MD, MPH
William O'Connell MD
Kenneth Ogan MD
Joel A Okoli MD MPH
Jeffrey J. Olson MD
Gabriela M. Oprea MD
Adeboye O. Osunkoya MD, FCAP
Taofeek K. Owonikoko MD
Nelson M. Oyesiku MD, PhD, FACS
Nicki Panoskaltsis MD, PhD, FRCP
Nicki Panoskaltsis MD, PhD, FRCP
Elisavet Paplomata MD
Douglas C. Parker MD
Pretesh Patel MD
Sagar A Patel MD
Allan Pickens MD
Rathi Pillai MD
Brian P Pollack MD, PhD
Suresh S. Ramalingam MD
William Read , MD
Satyanarayan K. Reddy MD
Nickolas B Reimer MD
Maria J. Ribeiro MD
Chad W Ritenour MD
Monica Rizzo MD
Steven M. Roser DMD, MD
Peter J. Rossi MD
Nabil F. Saba MD, FACP
Ruth Sacks MD
Manu S Sancheti
Martin G Sanda MD
Juan M. Sarmiento MD
Neil D Saunders MD
David M. Schuster MD
Judy H. Sequeira MD
Charles W. Sewell MD
Virginia O Shaffer MD
Mihir M Shah MD
Jyotirmay Sharma MD
Dong Moon Shin MD
Hui-Kuo G. Shu MD, PhD
Mark Shumate MD, MPH
Gabriel L. Sica MD
Momin T. Siddiqui MD, FIAC
William C. Small MD
Cyril O. Spann MD,SM, FACOG, FACS
Charles A. Staley MD
Liza J. Stapleford MD
Sidney F. Stein MD
Conor F Steuer
Toncred M. Styblo MD
Preeti D Subhedar MD, MSPT
Pakkala Suchita
Ajay Tadepalli MD
Talaat S. Tadros MD
Ahmad Tarhini MD, PhD
Meena Thirunavu MD
Mylin A. Torres MD
William E. Torres MD
Keriann M. Van Nostrand MD
Vijay Alluri Varma MD
Alfredo D. Voloschin MD
J. Trad Wadsworth MD
Edmund K. Waller MD, PhD, FACP
Mark D Walsh MD, FACS
Carl Washington MD
Sharon W. Weiss MD
Ifor R. Williams MD, PhD
Elliott F. Winton MD
Christina Wu MD
Howa Yeung MD
David Yu MD
Melinda L Yushak
Jim Zhong MD

Clinical Trials in Georgia

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cancer Type: Hematopoietic Malignancies, Leukemia, Unknown Primary

6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type: Unknown Primary

A Beta-only IL-2 ImmunoTherapY Study
Cancer Type: Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Cancer Type: Melanoma, Unknown Primary

A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
Cancer Type: Skin Cancer (Non-Melanoma), Unknown Primary

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
Cancer Type: Solid Tumor

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Cancer Type: Hematopoietic Malignancies
Study Coordinator: Heather Renfroe - 404-778-5127


A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
Cancer Type: Leukemia

A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Cancer Type: Multiple Myeloma

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type: Leukemia, Lymphoma

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Cancer Type: Eye Cancer, Melanoma, Unknown Primary

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
Cancer Type: Liver Cancer / Hepatoblastoma

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Melanoma, Unknown Primary

A Robot (My Special Aflac Duck) for the Reduction of Medical Setting Distress in Pediatric Cancer Patients
Cancer Type: Hematopoietic Malignancies, Solid Tumor

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Cancer Type: Hematopoietic Malignancies, Leukemia, Unknown Primary

A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Cancer Type: Unknown Primary

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
Cancer Type: Liver Cancer / Hepatoblastoma

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Cancer Type: Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Cancer Type: Breast Cancer, Unknown Primary

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Cancer Type: Lymphoma

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Cancer Type: Bladder Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Unknown Primary

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Cancer Type: Ovarian Cancer, Solid Tumor, Unknown Primary, Uterine Cancer

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

A Study of ASP1012 in Adults With Solid Tumors
Cancer Type: Melanoma, Stomach/ Gastric Cancer

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary

A Study of Daratumumab
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
Cancer Type: Hematopoietic Malignancies, Unknown Primary

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Cancer Type: Breast Cancer, Unknown Primary

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Cancer Type: Colon/Rectal Cancer, Lung Cancer, Solid Tumor

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Cancer Type: Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Cancer Type: Breast Cancer

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Cancer Type: Kidney Cancer, Unknown Primary

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Cancer Type: Unknown Primary

A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
Cancer Type: Solid Tumor, Unknown Primary

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C
Cancer Type: Lung Cancer

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Cancer Type: Esophogeal Cancer, Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Prostate Cancer

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Cancer Type: Cancer-Related Syndrome, Leukemia

A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
Cancer Type: Solid Tumor, Unknown Primary

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Cancer Type: Head and Neck Cancer

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Cancer Type: Leukemia

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary

A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
Cancer Type: Leukemia

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Cancer Type: Unknown Primary

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Cancer Type: Bladder Cancer, Unknown Primary

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Cancer Type: Bladder Cancer, Unknown Primary

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type: Colon/Rectal Cancer, Lung Cancer, Melanoma

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Cancer Type: Cervical Cancer

A Study of XMT-1660 in Participants With Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
Cancer Type: Solid Tumor, Unknown Primary

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Cancer Type: Germ Cell Tumor

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Cancer Type: Non-Hodgkin Lymphoma

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Cancer Type: Breast Cancer, Unknown Primary

A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
Cancer Type: Leukemia

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
Cancer Type: Sarcoma

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Cancer Type: Multiple Myeloma

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Cancer Type: Multiple Myeloma

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
Cancer Type: Unknown Primary

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Cancer Type: Liver Cancer / Hepatoblastoma

A Web-based Dyadic Intervention to Manage Psychoneurological Symptoms for Patients with Colorectal Cancer and Their Caregivers
Cancer Type: Colon/Rectal Cancer

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Cancer Type: Head and Neck Cancer

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Cancer Type: Solid Tumor

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Cancer Type: Leukemia

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Cancer Type: Breast Cancer, Unknown Primary

An Internet-Based Application for Improving Adherence to Endocrine Therapy among Patients with Early Stage Hormone Receptor Positive, HER2-Negative Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary

An Investigational Imaging Technique (Quantitative Oblique Back Illumination Microscopy) during Brain Surgery for the Detection of Brain Tumors and Brain Tumor Margins
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor

An Investigational Scan (18F-rhPSMA 7.3 PET/CT) with and without Furosemide for the Reduction of Bladder Activity in Patients with Biochemically Recurrent Prostate Cancer
Cancer Type: Prostate Cancer

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Cancer Type: Pancreatic Cancer

ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Cancer Type: Breast Cancer

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Cancer Type: Leukemia

Atezolizumab for the Treatment of Patients with Resectable, Human Papillomavirus Related Oropharyngeal Squamous Cell Carcinoma
Cancer Type: Head and Neck Cancer, Unknown Primary

Atezolizumab in Combination with Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma (AflacST2301)
Cancer Type: Bone Tumor

Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
Cancer Type: Liver Cancer / Hepatoblastoma

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors
Cancer Type: Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary

Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Cancer Type: Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary

Canakinumab and Darbepoetin Alfa for the Treatment of Lower-Risk Myelodysplastic Syndromes in Patients Who Have Failed Erythropoietin Stimulating Agents
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

CAR-T Long Term Follow Up (LTFU) Study
Cancer Type: Unknown Primary

Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation
Cancer Type: Lymphoma, Multiple Myeloma, Plasma cell neoplasm

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
Cancer Type: Lung Cancer

Cholecalciferol in Improving Survival in Patients with Newly Diagnosed Cancer with Vitamin D Insufficiency
Cancer Type: Leukemia, Lymphoma

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cancer Type: Leukemia, Myelodysplastic Syndromes (MDS)

Communication Issues in Patient and Provider Discussions of Immunotherapy
Cancer Type: Solid Tumor

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy, The Ice Compress Trial
Cancer Type: Solid Tumor

Comparing Inotuzumab Combined with Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults with CD22+ B-cell Acute Lymphoblastic Leukemia
Cancer Type: Leukemia

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplastic Syndrome-Related Changes
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Comparison of Surgery to Stereotactic Body Radiation Therapy (SBRT) in Patients With Stage I Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

DALY II USA/ MB-CART2019.1 for DLBCL
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma with Kidney Failure
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

DAREON??-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
Cancer Type: Lung Cancer

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Cancer Type: Neuroendocrine Tumor, Unknown Primary

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Cancer Type: Lung Cancer, Unknown Primary

Decision Support Training for Family Caregivers of Patients with Advanced Cancer, CASCADE Factorial Study
Cancer Type: Breast Cancer, Head and Neck Cancer, Lung Cancer, Melanoma

DECOY20 Study in Patients With Advanced Solid Tumors
Cancer Type: Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer

Docetaxel, Ramucirumab, and Pembrolizumab for the Treatment of Metastatic or Recurrent Non-small Cell Lung Cancer in Patients who have Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade Therapy
Cancer Type: Lung Cancer

Donor Immune Cells (Allogenic Ex Vivo Expanded Gamma Delta T Cells), Dinutuximab, Temozolomide, Irinotecan and Zoledronate for the Treatment of Refractory, Relapsed, or Progressive Neuroblastoma in Children
Cancer Type: Neuroblastoma

Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Cancer Type: Melanoma

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cancer Type: Leukemia, Myelodysplastic Syndromes (MDS)

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL
Cancer Type: Cancer-Related Syndrome

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Cancer Type: Solid Tumor

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Cancer Type: Colon/Rectal Cancer

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients
Cancer Type: Melanoma

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Cancer Type: Unknown Primary

Enfortumab Vedotin plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Cancer Type: Bladder Cancer

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Chemo-Immunotherapy with Pembrolizumab Before Surgery
Cancer Type: Breast Cancer

Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
Cancer Type: Prostate Cancer

Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma
Cancer Type: Hematopoietic Malignancies, Leukemia, Non-Hodgkin Lymphoma

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Cancer Type: Breast Cancer, Unknown Primary

Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study
Cancer Type: Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma

Evaluation of Sexual Toxicities in Women After Pelvic Radiotherapy
Cancer Type: Anal Cancer, Cervical Cancer, Colon/Rectal Cancer, Gynecologic Cancers, Solid Tumor, Uterine Cancer

Fatigue Assessment in Patients with Breast Cancer Undergoing Chemotherapy, Surgery, or Radiation Therapy
Cancer Type: Breast Cancer, Unknown Primary

Fiber-Rich Foods for the Treatment of Obesity and Prevention of Colon Cancer
Cancer Type: Colon/Rectal Cancer

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Cancer Type: Breast Cancer

Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Cancer Type: Hematopoietic Malignancies

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Cancer Type: Lung Cancer

First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Cancer Type: Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Lung Cancer, Ovarian Cancer, Stomach/ Gastric Cancer

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Cancer Type: Leukemia

Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET/CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma
Cancer Type: Prostate Cancer , Unknown Primary

GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
Cancer Type: Hematopoietic Malignancies, Leukemia, Multiple Myeloma

Genetic Information and Family Testing Platform to Facilitate Genetic Testing for Cancer Patients' Families, GIFT Study
Cancer Type: Solid Tumor

Genetic Testing in Guiding Treatment for Patients with Brain Metastases
Cancer Type: Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer, Unknown Primary

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary

HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

HPVIQ-PedOnc Intervention in Maximizing HPV Vaccine Uptake in Young Cancer Survivors
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Hypofractionated Proton or Photon Radiation Therapy for the Treatment of Brain Tumors, the HiPPI Study
Cancer Type: Brain & Spinal Cord Tumor

Identification of Treatment Concentrations of Defactinib or Avutometinib for the Treatment of Patients with Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor

ILND Surgery Alone or after Chemotherapy with or without Radiation Therapy in Treating Patients with Advanced Penile Cancer
Cancer Type: Penile Cancer

Immunotherapy in Combination with Prednisone and Sirolimus for Kidney Transplant Recipients with Unresectable or Metastatic Skin Cancer
Cancer Type: Melanoma

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Cancer Type: Leukemia

International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Cancer Type: Prostate Cancer

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Cancer Type: Breast Cancer

Ketorolac before Surgery for the Treatment of Stage I-II Non-small Cell Lung Cancer or Stage III Renal Cell Cancer
Cancer Type: Lung Cancer

KZR-261 in Subjects With Advanced Solid Malignancies
Cancer Type: Colon/Rectal Cancer, Eye Cancer, Melanoma, Prostate Cancer , Solid Tumor, Unknown Primary

Letrozole with and without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
Cancer Type: Breast Cancer

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients with Multiple Myeloma
Cancer Type: Bone Tumor, Multiple Myeloma, Plasma cell neoplasm

Metformin for the Prevention of Oral Cancer in Patients with Oral Leukoplakia or Erythroplakia
Cancer Type: Unknown Primary

Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Cancer Type: Prostate Cancer

Mobile Health for Adherence in Breast Cancer Patients
Cancer Type: Breast Cancer

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Cancer Type: Leukemia

Modified Immune Cells (Autologous iC9.GD2.CAR.IL-15 T cells) for Treating Patients with Relapsed or Refractory High Risk Neuroblastoma, Ganglioneuroblastoma, or Osteosarcoma
Cancer Type: Neuroblastoma, Neurologocal Tumor, Sarcoma

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Cancer Type: Hematopoietic Malignancies, Melanoma

Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Cancer Type: Hematopoietic Malignancies, Solid Tumor

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Cancer Type: Brain & Spinal Cord Tumor

ONC206 for the Treatment of Newly Diagnosed or Recurrent Diffuse Midline Gliomas or Other Recurrent Primary Malignant Central Nervous System Tumors
Cancer Type: Brain & Spinal Cord Tumor

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type: Multiple Myeloma

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients with Advanced Cancer
Cancer Type: Breast Cancer, Ovarian Cancer

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
Cancer Type: Breast Cancer

Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer

Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Cancer Type: Lung Cancer

Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Cancer Type: Lung Cancer

Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
Cancer Type: Unknown Primary

Paricalcitol and Hydroxychloroquine in Combination with Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer
Cancer Type: Pancreatic Cancer, Unknown Primary

Pembrolizumab with and without Intra-operative Radiation Therapy in Treating Patients with Triple Negative Breast Cancer
Cancer Type: Breast Cancer

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients with Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
Cancer Type: Stomach/ Gastric Cancer

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Cancer Type: Head and Neck Cancer, Sarcoma, Solid Tumor

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Cancer Type: Colon/Rectal Cancer, Sarcoma, Solid Tumor

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Cancer Type: Colon/Rectal Cancer, Melanoma, Ovarian Cancer

Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors
Cancer Type: Brain & Spinal Cord Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Solid Tumor, Unknown Primary

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
Cancer Type: Prostate Cancer

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
Cancer Type: Solid Tumor, Unknown Primary

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Radiation Medication (Radium-223 dichloride) versus Radium-223 dichloride plus Radiation Enhancing Medication (M3814) versus Radium-223 dichloride plus M3814 plus Avelumab (a type of immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Cancer Type: Prostate Cancer

Radiation Therapy with or without Cisplatin in Treating Patients with Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Cancer Type: Head and Neck Cancer

Radioligand Therapy after PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients with Biochemically Recurrent Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Cancer Type: Brain & Spinal Cord Tumor

Registry Study for Radiation Therapy Outcomes
Cancer Type: Solid Tumor

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Cancer Type: Liver Cancer / Hepatoblastoma, Unknown Primary

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Cancer Type: Ovarian Cancer

REtroperitoneal SArcoma Registry: an International Prospective Initiative
Cancer Type: Sarcoma

Rifaximin in Treating Patients with Monoclonal Gammopathy
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Robotic vs. Open NSM for Early Stage Breast Cancer
Cancer Type: Breast Cancer

Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors
Cancer Type: Lung Cancer, Solid Tumor

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Cancer Type: Leukemia

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial
Cancer Type: Cervical Cancer

Sirolimus and Metronomic Chemotherapy for the Treatment of High-Risk Solid Tumors in Children, AflacST1903 Study
Cancer Type: Sarcoma, Solid Tumor

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Cancer Type: Solid Tumor, Unknown Primary

Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab for the Treatment of Locally Advanced or Metastatic Cancer
Cancer Type: Solid Tumor, Unknown Primary

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors with NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Cancer Type: Melanoma

Stereotactic Radiosurgery or Hippocampus Avoidance Whole-Brain Radiation Therapy with Memantine in Treating Patients with 5 or more Brain Metastases
Cancer Type: Brain & Spinal Cord Tumor, Unknown Primary

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer

Study of AZD0754 in Participants With Metastatic Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Cancer Type: Leukemia

Study of CHS-114 in Participants With Advanced Solid Tumors
Cancer Type: Head and Neck Cancer, Skin Cancer (Non-Melanoma), Solid Tumor, Unknown Primary

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Cancer Type: Leukemia

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Cancer Type: Lung Cancer, Melanoma, Stomach/ Gastric Cancer

Study of INCB123667 in Subjects With Advanced Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

Study of PYX-106 in Solid Tumors
Cancer Type: Uterine Cancer

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Cancer Type: Unknown Primary

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Cancer Type: Cervical Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Sarcoma, Skin Cancer (Non-Melanoma), Solid Tumor, Unknown Primary

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Cancer Type: Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Unknown Primary

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type: Kidney Cancer, Unknown Primary

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Cancer Type: Solid Tumor, Unknown Primary

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm

TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Cancer Type: Bile Duct Cancer

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Cancer Type: Kidney Cancer

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy versus Standard of Care Chemotherapy Alone for Patients with Unresectable Colorectal Liver Metastases: The PUMP Trial
Cancer Type: Colon/Rectal Cancer

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients with High Risk Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) after Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors that have Returned after Previous Treatment
Cancer Type: Brain & Spinal Cord Tumor, Unknown Primary

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer
Cancer Type: Unknown Primary

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Cancer Type: Lung Cancer

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients with Advanced Solid Tumors, The ComBET Trial
Cancer Type: Solid Tumor, Unknown Primary

Testing the Combination of two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
Cancer Type: Neuroendocrine Tumor, Skin Cancer (Non-Melanoma), Unknown Primary

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Cancer Type: Bladder Cancer, Kidney Cancer, Penile Cancer, Urethral Cancer

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
Cancer Type: Lung Cancer

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Cancer Type: Neuroendocrine Tumor, Unknown Primary

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab with or without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
Cancer Type: Head and Neck Cancer

TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia
Cancer Type: Leukemia

The Use of the LuViva Advanced Cervical Scan to Identify Women at High-Risk for Cervical Neoplasia
Cancer Type: Unknown Primary

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients with Stage I-III Early Stage Breast Cancer
Cancer Type: Breast Cancer

Treatment Response and Biomarker-Guided Steroid Taper for Children with GVHD
Cancer Type: Unknown Primary

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Tumor Treating Fields for the Treatment of Brainstem Gliomas
Cancer Type: Brain & Spinal Cord Tumor

Venetoclax and Tocilizumab for the treatment of Patients with Relapsed or Refractory t(11;14) Multiple Myeloma
Cancer Type: Multiple Myeloma

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
Cancer Type: Hematopoietic Malignancies, Unknown Primary

Vidutolimod (CMP-001) in Combination with Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas
Cancer Type: Brain & Spinal Cord Tumor

Vorinostat in Preventing Graft Versus Host Disease in Children, Adolescents, and Young Adults Undergoing Blood and Bone Marrow Transplant
Cancer Type: Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma

Vudalimab in Combination with Standard of Care Treatment in Patients with Metastatic Castration Sensitive Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Cancer Type: Lymphoma, Non-Hodgkin Lymphoma
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.